Regenxbio (RGNX) news
Recent news
Regenxbio Inc.: H.C. Wainwright cuts target price to $21 from $23
H.C. Wainwright has lowered its price target for Regenxbio Inc. (NASDAQ: RGNX) to $21 from $23, while maintaining a "Buy" rating . The adjustment follows the firm’s recent assessment of the company’s financial and regulatory developments, including its public equity offering in July 2026 and the…
AInvest Wire · 6d agoRegenXBio: Karabelas, Bennett retire from board
AInvest Wire · 6d agoRegenxbio strengthens board of directors with appointment of Greg Ciongoli
AInvest Wire · 6d agoRegenxbio Inc.: Clear Street cuts target price to $32 from $45
AInvest Wire · 6d agoRegenxbio shares down 24% after FDA places clinical hold on company's gene therapy for Hunter syndrome
Regenxbio Inc. (NASDAQ: RGNX) experienced a significant decline in its stock price, dropping 24% following the U.S. Food and Drug Administration’s (FDA) decision to place a clinical hold on RGX-121 , for the treatment of Hunter syndrome (Mucopolysaccharidosis II, or MPS II). The FDA also extended…
AInvest Wire · 7d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.